

REGENERON PHARMACEUTICALS INC  
Form 3  
March 02, 2017

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol                         |  |
| Â Fenimore Christopher R.                 |         | (Month/Day/Year)                     | REGENERON PHARMACEUTICALS INC [REGN]                                       |  |
| (Last)                                    | (First) | (Middle)                             | 03/02/2017   |  |
| 777 OLD SAW MILL RIVER RD                 |         |                                      | 4. Relationship of Reporting Person(s) to Issuer                           | 5. If Amendment, Date Original Filed(Month/Day/Year)                   |
| (Street)                                  |         |                                      | (Check all applicable)   |  |
| TARRYTOWN,Â NYÂ 10591                     |         |                                      | <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner       | 6. Individual or Joint/Group Filing(Check Applicable Line)             |
| (City)                                    | (State) | (Zip)                                | <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
|   |         |                                      | (give title below) (specify below)   | <input type="checkbox"/> Form filed by More than One Reporting Person  |
|   |         |                                      | VP, Controller   |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 1,328   | I  | By 401(k) Plan  |
| Common Stock                    | 2,695   | I  | By GRAT   |
| Common Stock                    | 4,297   | I  | By Trust <sup>(1)</sup>                               |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying | 4. Conversion | 5. Ownership | 6. Nature of Indirect Beneficial |
|--|--|--|---------------|--------------|----------------------------------|
|--|--|--|---------------|--------------|----------------------------------|

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

|   | Date Exercisable | Expiration Date | Derivative Security (Instr. 4)<br>Title | Amount or Number of Shares | or Exercise Price of Derivative Security | Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | Ownership (Instr. 5) |
|---|------------------|-----------------|---|----------------------------|--|--|----------------------|
| Incentive Stock Option (right to buy)     | Â (2)            | 12/18/2019      | Common Stock                            | 1,375                      | \$ 21.25                                 | D  | Â                    |
| Incentive Stock Option (right to buy)     | Â (2)            | 12/14/2020      | Common Stock                            | 4,280                      | \$ 30.63                                 | D  | Â                    |
| Incentive Stock Option (right to buy)     | Â (2)            | 12/16/2021      | Common Stock                            | 2,224                      | \$ 52.03                                 | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (2)            | 12/16/2021      | Common Stock                            | 13,776                     | \$ 52.03                                 | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (3)            | 12/14/2022      | Common Stock                            | 23,500                     | \$ 179.13                                | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (3)            | 12/13/2023      | Common Stock                            | 20,000                     | \$ 270.43                                | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (3)            | 12/16/2026      | Common Stock                            | 12,283                     | \$ 381.92                                | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (3)            | 12/16/2024      | Common Stock                            | 17,000                     | \$ 399.66                                | D  | Â                    |
| Non-Qualified Stock Option (right to buy) | Â (3)            | 12/16/2025      | Common Stock                            | 14,450                     | \$ 555.67                                | D  | Â                    |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                  |       |
|---|---------------|-----------|------------------|-------|
|   | Director      | 10% Owner | Officer          | Other |
| Fenimore Christopher R.<br>777 OLD SAW MILL RIVER RD<br>TARRYTOWN, NY 10591 | Â             | Â         | Â VP, Controller | Â     |

## Signatures

/s/\*\*Christopher R.  
Fenimore

03/02/2017

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

- (2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (3) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.